Hyperfine (NASDAQ:HYPR – Get Free Report) is expected to be posting its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect Hyperfine to post earnings of ($0.09) per share and revenue of $3.54 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.
Hyperfine (NASDAQ:HYPR – Get Free Report) last announced its quarterly earnings results on Wednesday, March 18th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. Hyperfine had a negative net margin of 262.29% and a negative return on equity of 95.09%. The firm had revenue of $5.29 million during the quarter, compared to analysts’ expectations of $5.30 million.
Hyperfine Stock Down 4.7%
HYPR stock traded down $0.09 during trading on Tuesday, hitting $1.73. The company had a trading volume of 508,887 shares, compared to its average volume of 535,316. The firm has a 50-day moving average price of $1.19 and a 200-day moving average price of $1.14. Hyperfine has a 12 month low of $0.53 and a 12 month high of $2.22. The stock has a market cap of $168.98 million, a price-to-earnings ratio of -3.92 and a beta of 1.42.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on Hyperfine
Insider Activity
In other Hyperfine news, COO Thomas Teisseyre sold 24,188 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $1.21, for a total value of $29,267.48. Following the transaction, the chief operating officer directly owned 354,648 shares of the company’s stock, valued at $429,124.08. This represents a 6.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Brett Hale sold 24,188 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $1.21, for a total transaction of $29,267.48. Following the completion of the transaction, the chief financial officer directly owned 275,812 shares in the company, valued at approximately $333,732.52. This represents a 8.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 26.33% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its stake in Hyperfine by 674.4% in the 4th quarter. Renaissance Technologies LLC now owns 364,743 shares of the company’s stock valued at $357,000 after purchasing an additional 317,645 shares during the last quarter. Walleye Capital LLC bought a new position in Hyperfine during the fourth quarter worth $212,000. Vanguard Group Inc. raised its stake in Hyperfine by 5.7% during the third quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company’s stock worth $5,092,000 after buying an additional 190,136 shares during the last quarter. Geode Capital Management LLC grew its holdings in Hyperfine by 21.4% in the fourth quarter. Geode Capital Management LLC now owns 815,986 shares of the company’s stock worth $799,000 after purchasing an additional 143,975 shares during the period. Finally, Cerity Partners LLC acquired a new stake in Hyperfine in the fourth quarter worth $59,000. Institutional investors and hedge funds own 15.03% of the company’s stock.
Hyperfine Company Profile
Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.
The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.
Further Reading
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
